Dis­ap­point­ment at can­cer drug de­ci­sion

Yorkshire Post - - NEWS -

The In­sti­tute of Can­cer Re­search says it is “dis­ap­point­ing” that health lead­ers have de­cided not to rec­om­mend a drug for women with ad­vanced ovar­ian can­cer.

The Na­tional In­sti­tute for Health and Care Ex­cel­lence has pub­lished draft guid­ance which does not rec­om­mended ola­parib tablets as a main­te­nance treat­ment for adults with re­lapsed, plat­inum-sen­si­tive ovar­ian, fal­lop­ian tube and peri­toneal can­cer.

Newspapers in English

Newspapers from UK

© PressReader. All rights reserved.